Investor Relations

Latest Financial Results

Q3 2020

Quarter Ended Sep 30, 2020

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2019

Company Overview

CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing.

Our revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, we are developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics.

Our mission at CollPlant is to deliver ground-breaking products for regenerative medicine that offer the optimal treatment options to patients.

Investor Contact Information

Company

CollPlant Biotechnologies Ltd.
4 Oppenheimer St.,
P.O.B 4132
Rehovot 7670104,
Israel

Investor Relations

Eran Rotem
Deputy CEO & CFO
T: +972 (73) 2325612
F: +972 (73) 2325602
eran@collplant.com

Transfer Agent

The Bank of New York Mellon
Depositary Receipts Division - Global Client Solutions
Arlene C. Villareal
Vice President
101 Barclay Street, 22W
New York, NY 10286
T: 212-815-8162
Arlene.villareal@bnymellon.com

Details

exploreCollPlant Ltd

4 Oppenheimer Street
P.O. Box 4132
Rehovot 7670104, Israel

local_phone+972 73 2325600
local_printshop+972 73 2325602

 
 

® 2020 CollPlant Biotechnologies Ltd. All rights reserved. Version: CPW 02-20

Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.